Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I work in pharmaceutical business development and commercial operation & strategy in the GCC, with strong exposure to the KSA & UAE markets in particular. My experience spans marketing & sales management, portfolio evaluation, distributor selection, market-entry planning, pricing logic, and commercial execution across both specialty and broader prescription-driven categories.

Q2. With the 2026 mandates for local production in the UAE and Saudi Arabia, what is the 'true' margin benefit of shifting from an import model to a locally-contract-manufactured one?

The real benefit is usually not a simple gross-margin uplift; it is a strategic mix of regulatory alignment, faster replenishment, lower supply-chain friction, and better tender positioning as both the UAE and KSA continue to push industrial localization. In practice, the net gain depends on scale, tech-transfer complexity, batch economics, and whether the product has enough volume to absorb the local operating structure within GCC.

Q3. As reference biologics worth billions lose exclusivity in 2026, what is the 'Ground-Level' timeline for biosimilar absorption in the GCC hospital sector?

On the ground, biosimilar absorption is rarely immediate; real uptake usually starts after registration, formulary acceptance, tender positioning, and physician confidence begin to align. In practical terms, I would expect a phased curve, with faster movement in centralized public systems 1st and a slower, more relationship-driven ramp in segments where switching behavior remains clinically and institutionally cautious. The role of MSL is really needed in that.

Q4. With sea-route surcharges and new energy efficiency mandates impacting cold-chain costs in 2026, how are companies balancing the 'Zero-Tolerance' storage for biologics? Is the cost of precision cooling making certain low-margin specialty products unviable to distribute?

Zero-tolerance handling for biologics is still non-negotiable, so companies are responding through best effective & efficient technology selection, better inventory placement, shipment consolidation, and more disciplined portfolio prioritization rather than compromising storage standards. That said, rising compliance and transport costs are absolutely making some low-margin low/medium value specialty lines harder to justify from business perspective unless they are strategically important on country level, so some support may be expected from government. 

Q5. With the recent consolidation of regional distributors, what is the 'Days Sales Outstanding' (DSO) trend you are seeing on the ground? Are we seeing payments from public healthcare entities accelerating or slowing down in the first half of 2026?

My view is that the market remains mixed rather than uniformly improving; scale and consolidation may strengthen negotiating power, but they do not automatically shorten receivable cycles. In the first half of 2026, I would describe public-sector payment behavior as generally selective and entity-dependent, with companies give closer attention to contract structure, and working-capital discipline than to growth alone.

Q6. In the current 2026 landscape, is the higher OpEx required for 'Specialty' segments (Oncology, Gene Therapy, CNS) yielding a proportional net margin increase compared to high-volume 'Primary Care' generics, or is the cost-to-serve eating the premium?

Specialty can still generate better economics, but only when the company has the right infrastructure and enough commercial density to support the model. In most of cases: volumes are fragmented and the service burden is high, unless you have the right setup managing small volumes / high value products: the margin can be diluted quickly by medical, access, cold-chain, pharmacovigilance, and account-management costs; so the answer is not “specialty always wins,” but “specialty wins only when execution quality is structurally strong.”

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I would ask: How much of your reported margin is truly structural, and how much is being overstated by underestimating cost-to-serve and working-capital intensity by category, customer type, and channel? In this sector, the strongest businesses are not just the ones that grow fast, but the ones that can prove disciplined profitability, cash conversion, and portfolio resilience under real operating pressure.